Lesetja V. Ramoba

Lesetja V. Ramoba

Auto-generated profile, based on publicly available information

Lesetja V. Ramoba

Department of Chemistry, Tshwane University of Technology, P.O. Box X680, Pretoria 0001, South Africa

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2025 in ACS Omega
Verified
Journal Article
Open access
LRLesetja V. Ramoba
Lesetja V. Ramoba
WNWakopo J. Nzondomyo
Wakopo J. Nzondomyo
KSKarabo Serala
Karabo Serala
LMLucy W. Macharia
Lucy W. Macharia
SBSupratim Biswas
Supratim Biswas
AMAmanda-Lee Ezra Manicum
Amanda-Lee Ezra Manicum
Five pyrazole-based compounds, 3,5-dimethyl-1H-pyrazole, L1; 3,5-diphenyl-1H-pyrazole, L2; 3-(trifluoromethyl)-5-phenyl-1H-pyrazole, L3; 3-(trifluoromethyl)-5-methyl-1H-pyrazole, L4; and 3,5-ditert-butyl-1H-pyrazole, L5 were synthesized from a typical condensation reaction of β-diketone derivatives with hydrazine hydrate reagent and characterized using various spectroscopic techniques such as FT-IR, UV-vis, 1H and 13C NMR, and LC-MS spectroscopy. L1 was further analyzed by single-crystal X-ray diffraction, and the N1-N1' bond distance was found to be 1.361(3) Å and correlated well with other pyrazole-based compounds. The short-term cytotoxicity of 10 μM pyrazole compounds (L1-L5) was evaluated against pancreatic (CFPAC-1 and PANC-1), breast (MDA-MB-231 and MCF-7), and cervical (CaSki and HeLa) cancer cell lines using the MTT cell viability assay. Cisplatin and gemcitabine were included as positive control drugs followed by the determination of the half-maximal effective concentrations of prospective compounds. L2 and L3, respectively, displayed moderate cytotoxicity against CFPAC-1 (61.7 ± 4.9 μM) and MCF-7 (81.48 ± 0.89 μM) cell lines.

22 May 2020 in Zeitschrift für Kristallographie - New Crystal Structures
Verified
Journal Article
Open access
PDF file
LRLesetja V. Ramoba
Lesetja V. Ramoba
OAOrbett Teboho Alexander
Orbett Teboho Alexander
HVHendrik G. Visser
Hendrik G. Visser
AMAmanda-Lee E. Manicum
Amanda-Lee E. Manicum
C18H12O3N4Re, triclinic, P1̄ (no. 2), a = 8.3476(15) Å, b = 9.5742(17) Å, c = 12.435(2) Å, α = 87.606(5)°, β = 74.502(5)°, γ = 88.028(5)°, V = 956.6(3) Å3, Z = 2, R gt(F) = 0.0213, wR ref(F 2) = 0.0523, T = 100(2) K.

17 September 2025 in Journal of Molecular Structure
Verified
Journal Article
Open access
LRLesetja V. Ramoba
Lesetja V. Ramoba
LMLucy W. Macharia
Lucy W. Macharia
SCSuparna Chakraborty
Suparna Chakraborty
Sharon PrinceSharon Prince
Sharon Prince
FMFrederick P. Malan
Frederick P. Malan
AMAmanda-Lee Ezra Manicum
Amanda-Lee Ezra Manicum

19 June 2024 in Zeitschrift für Kristallographie - New Crystal Structures
Verified
Journal Article
Open access
PDF file
LRLesetja V. Ramoba
Lesetja V. Ramoba
OAOrbett Teboho Alexander
Orbett Teboho Alexander
FMFrederick P. Malan
Frederick P. Malan
AMAmanda-Lee E. Manicum
Amanda-Lee E. Manicum
C18H23N7O6Re, triclinic, P 1 ‾ $\overline{1}$ (no. 2), a = 10.527(2) Å, b = 10.849(2) Å, c = 11.215(2) Å, α = 72.798(2)°, β = 69.767(2)°, γ = 87.496(10)°, V = 1145.52(4) Å3, Z = 2, R gt(F) = 0.0273, wR ref(F 2) = 0.0727, T = 150(2) K.

7 July 2026 in Journal of Inorganic Biochemistry
Verified
Journal Article
Open access
LRLesetja V. Ramoba
Lesetja V. Ramoba
ADAmani Direm
Amani Direm
FHFarida Hakkar
Farida Hakkar
CPCemal Parlak
Cemal Parlak
LMLucy W. Macharia
Lucy W. Macharia
AMAmanda-Lee E. Manicum
Amanda-Lee E. Manicum
Rhenium tricarbonyl complexes in their monometallic forms have been extensively studied, mainly for their potent inhibitory activity against cancer cells. However, far fewer dinuclear complexes have been investigated for similar applications. In this study, we report the synthesis, crystal structure, DFT analysis, in vitro biological screening, and in silico molecular docking of the complex NEt4[{Re(CO)3}2-μ-(OCH3)2-μ-(3,5-Me2py)], C1 (where OCH3 = methoxy; 3,5-Me2py = 3,5-dimethyl-1H-pyrazolate). This dinuclear complex, C1, was characterised spectroscopically by FT-IR, 1H and 13C NMR, UV-Vis, as well as single-crystal X-ray diffraction. Preliminary in vitro screening at a single dose of 10 μM in DMSO revealed excellent cytotoxicity of C1 against cervical (HeLa and CaSki), pancreatic (PANC-1 and CFPAC-1), and breast (MCF-7) cancer cell lines. It was further evaluated for its half-maximal inhibitory concentration (IC50) which was determined as 1.59 ± 0.34 (SI = 6.39), 1.06 ± 0.35 (SI = 9.59), 0.74 ± 0.22 (SI = 13.73), 3.58 ± 0.10 (SI = 2.83) and 2.24 ± 0.45 (SI = 4.54) μM against HeLa, CaSki, CFPAC-1, PANC-1 and MCF-7, respectively, while the IC50 against MRC-5 (non-cancerous human fibroblast cells) was 10.16 ± 0.8 μM. The DFT calculations indicated that C1 is both reactive and conductive, with an energy gap (EHOMO-ELUMO) of 4.11 eV. Additionally, C1 was docked against tubulin to illustrate its potential binding modes to the target tubulin, and the in silico molecular docking results revealed binding affinities ranging from -5.43 to -4.37 kcal/mol.

23 May 2023 in Zeitschrift für Kristallographie - New Crystal Structures
Verified
Journal Article
Open access
PDF file
LRLesetja V. Ramoba
Lesetja V. Ramoba
OAOrbett Teboho Alexander
Orbett Teboho Alexander
FMFrederick P. Malan
Frederick P. Malan
AMAmanda-Lee E. Manicum
Amanda-Lee E. Manicum
C15H16O3N4Re, triclinic, P1̄ (no. 2), a = 7.4939(2) Å, b = 10.1316(2) Å, c = 13.8351(3) Å, α = 103.453(2)°, β = 101.992(2)°, γ = 107.880(2)°, V = 926.98(4) Å3, Z = 2, R gt (F) = 0.0341, wR ref (F 2) = 0.0861, T = 150 K.